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Virus-host interactionImmunosenescence, deﬁned as the age-associated dysregulation and dysfunction of the immune system, is
characterized by impaired protective immunity and decreased efﬁcacy of vaccines. An increasing number of im-
munological, clinical and epidemiological studies suggest that persistent Cytomegalovirus (CMV) infection is as-
sociated with accelerated aging of the immune system and with several age-related diseases. However, current
evidence on whether and how human CMV (HCMV) infection is implicated in immunosenescence and in age-
related diseases remains incomplete andmany aspects of CMV involvement in immune aging remain controver-
sial. The attendees of the 4th International Workshop on “CMV & Immunosenescence”, held in Parma, Italy,
25–27th March, 2013, presented and discussed data related to these open questions, which are reported in
this commentary.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
After primary infection, CMV is carried for the lifetime of its host.
Viral persistence is based on complex interactions between multiple
viral and host determinants. These interactions generally result in a
carefully negotiated and clinically “innocuous” balance between the
virus and the immunocompetent host. Indeed, CMV rarely produces
symptoms in the host unless the balance is upset by reduced immune
competency of the host (Fig. 1). Thus, when considering various types
of viral–host interaction, the overt CMV reactivation in immunocom-
promised individuals is a well recognizable disease state. By contrast,
the co-existence of human CMV in healthy, and evenmore so, in elderly
individuals is still a poorly understood phenomenon whose clinical and
host:pathogen correlates remain to be deﬁned. Speciﬁcally, at the
present time we still lack precise measures of viral load, viral latency
or reactivation status, of the type and extent/efﬁcacy of immune surveil-
lance, and of the interplay between the virus and the immune system
with regard to the true outcome of CMV infection (Latency with no
viral replication? Persistence with sporadic or frequent replication/
reactivations?), ultimately including its clinical impact.
The International Workshop on “CMV & Immunosenescence”, held
in Parma, Italy, 25–27th March, 2013, (local organizer Paolo Sansoni)
was the fourth of a series of such meetings. It brought together virolo-
gists, immunologists and geriatricians with the aim to present and dis-
cuss advances in our understanding of the impact of HCMV infection
on immune status and function, particularly focusing on its clinical sig-
niﬁcance in the elderly. As in the previous workshops, the results of
which were summarized in the corresponding reports (Pawelec et al.,
2010; Solana et al., 2012; Wills et al., 2011), communication andFig. 1. Host:HCMVexchange of the most recent ﬁndings among experts in this ﬁeld were
followed by discussion and deﬁnition of new perspectives.
The sessions of the 4thWorkshop covered a large spectrum of inter-
connected themes and were intended: (A) to clarify the basic mecha-
nisms of the virus–host interaction during primary and latent HCMV
infection; (B) to characterize how HCMV-speciﬁc immune surveillance
may remodel the immune system in the course of the life-long persis-
tent infection and thus, concomitantly impact the aging of the host;
(C) to answer whether HCMV is detrimental, neutral or perhaps even
beneﬁcial to immune defense; and (D) to explore the clinical signiﬁ-
cance of HCMV infection in a broad range of age-related pathologies.
For each theme, lessons from mouse model of CMV infection (MCMV)
have also been taken into account and integrated with human infection
data. In the ﬁnal round table with closing remarks, knowledge gaps
have been identiﬁed and priority areas for further research were
suggested.
2. Basic mechanisms of the virus–host interaction during primary
and latent HCMV infection
Intense research about the biology of CMV is required to clarify how
this virus establishes latency in spite of a robust immune response that
involves both innate and adaptive humoral and cell-mediated immuni-
ty. In that regard, HCMV-encoded determinants of tropism for endothe-
lial cells, an important target of the infection, have been investigated
(F. Goodrum, Tucson, USA) (Bughio et al., 2013). It was reported that
the UL133–UL138 locus, encoded within the ULb′ region of HCMV ge-
nome, is required for late stage tropism of the virus speciﬁcally in endo-
thelial cells. This locus is not required for early gene expression, viralinteraction.
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quired for maintaining membrane organization in the infected cell and
for the maturation of progeny viruses. Infection with viruses lacking
the UL133–UL138 region produced progeny viruses that lacked tegu-
ment and envelopes, resulting in a striking defect in virus yields. This
defect is not apparent in ﬁbroblasts or epithelial cells infected with the
UL133–UL138–Null virus, suggesting the identiﬁcation of the ﬁrst late-
stage, endothelial cell-speciﬁc tropism factors. Genes UL135 and
UL136, encoded within the UL133–UL138 locus, have been found im-
portant for maturation and, currently, the mechanisms by which they
function to promote virus maturation are under investigation. More re-
cent data suggest that this locus contains the key molecular switch be-
tween latency and reactivation, including the opposing roles of UL135
and UL138 (Umashankar et al., 2014).
R. Arens (Leiden, The Netherlands) discussed how in the course of
the early virus–host interaction, the outcome of anti-viral immunity
may be inﬂuenced by several viral determinants, including CMV strain,
virulence, MHC I downregulation and other escape mechanisms. In an
experimental CMV model, the impact of the viral dose on the outcome
of memory T cell inﬂation (an accumulation of large numbers of mem-
ory T cells that occurs during persistent MCMV infection), has been ex-
amined. It has been observed that a low-dose inoculum of mouse CMV,
as compared to intermediate and high dosages, does not elicit memory
T cell inﬂation. Following low-dose infection, already early after infec-
tion the phenotype of inﬂationary T cells is more central-memory-like
as evidenced by increased IL-2 production and decreased KLRG-1
expression. Both after low and intermediate dose infection, inﬂationary
T cells did not show signs of T cell exhaustion. These results suggest that
the initial viral dose impacts the outcome of MCMV infection by
inﬂuencing quality and extent of memory T cell inﬂation.
Neutralizing antibodies play an important role in the control of CMV
infection. However, little is known about the quality and the dynamics
of the primary B cell response induced by the virus. During primary in-
fection, large expansions of activated memory B cells (CD20+
CD21lowCD27+, phenotypically distinct from plasma cells) recognize
HCMVtegument proteins,whereas envelope glycoproteins are predom-
inantly recognized by classical memory B cells (CD20+ CD21+
CD27+) (A. Marchant, Brussels, Belgium). Primary infection is also
associated with high frequencies of HCMV-speciﬁc atypical memory B
cells (CD20+ CD21lowCD27−) expressing high levels of inhibitory re-
ceptors. The limited induction of envelope glycoprotein-speciﬁc effector
B cells and the induction of atypical memory B cells may limit the
production of neutralizing antibodies during primary CMV infection
and favour the dissemination of the virus, and subsequent establish-
ment of latency.
3. How HCMV-speciﬁc immune surveillance remodels the
immune system
The profound impact of HCMV on immune homeostasis and its con-
tribution tomany age-related changes observed in the immune system,
especially among T cells, have been subject of intense studies in the last
years. In concert with that, new data was reported on both innate and
adaptive responses to CMV.
It is known that HCMV infection in healthy individuals is associated
with an increase of NK cells expressing the CD94/NKG2C activating re-
ceptor, but the precise role of NKG2C+ cells in the control of HCMV in-
fection and the molecular mechanisms underlying the reconﬁguration
of the NK cell compartment remain open issues. Recent studies
(M. López-Botet, A. Muntasell Barcelona, Spain) have documented
the existence of two NKG2C+NK-cell subsets differing in surface stain-
ing intensity (Muntasell et al., 2013). The NKG2Cbright phenotype,
exclusively found in a subgroup of HCMV+ individuals (~50%) correlat-
ed with the expansion of NKG2C+NK cells. Conversely, the NKG2Cdim
NK phenotype was found in smaller proportions in the other half of
HCMV+ and all of the HCMV-negative donors. Because a homozygousdeletion of the NKG2C gene has been reported in different populations,
the possible inﬂuence of this genetic trait on NKR distribution was ad-
dressed. HCMV+ NKG2C+/+children and adults tend to possess,
under steady state conditions, greater numbers of NKG2Cbright cells
as compared to those in hemizygous NKG2C+/del subjects. In addition
to quantitative differences, differences in functional response to
receptor engagement were also noticed between NKG2C+/+and
NKG2C+/del subjects. These data support a correlation between
NKG2C zygosity and the magnitude/persistence of the NK-cell redistri-
bution in healthy HCMV+ donors.
Other studies examined characteristics of the gamma-delta T cell
response to HCMV. γδ T cells display considerable HCMV-associated
expansion and appear to contribute to the control of viremia. Most γδ
T cells are signiﬁcantly affected by age and are present at decreased
frequencies in the elderly. However, HCMV infectionmaintains a robust
and stable pool of Vδ2-negative γδ T cells throughout life. HCMV sero-
positivity accentuates further the accumulation of highly differentiated
lymphocytes in theVδ2-γδ T cell subsetswith time, in contrast to Vδ2+
γδ T cells, which maintain a less differentiated phenotype (D. Sauce,
Paris, France) (Roux et al., 2013). Moreover, the γδ T cell repertoire is
more restricted in HCMV-infected compared to non-infected individ-
uals. Together, these ﬁndings suggest that HCMV induces alterations
in γδ T cells similar to those reported for CD8 T cells that are associated
with immunosenescence. A crucial question is: what are the HCMV-
related antigens that support these γδ T cell responses? A new strategy
for the identiﬁcation of γδ T cell antigens expressed by HCMV-infected
cells has led to the identiﬁcation of EPCR (endothelial protein C recep-
tor) and EphA2 (a receptor tyrosine kinase for members of the ephrin-
A family) as antigens directly recognized by two different γδ receptors
(Vγ5Vδ5 and Vγ9Vδ1, respectively) on the surface of infected cells.
Free chains of HLA-I molecules are also recognized by Vγ9Vδ3-
expressing γδ T cells. These data are very intriguing because they
suggest that infection with HCMV activates γδ T cells speciﬁc for self
antigens through the induction of a multimolecular stress signature on
the surface of infected cells (J. Déchanet-Merville, Bordeaux, France)
(Willcox et al., 2012).
A number of presentations addressed the changes in the CD8+T cell
compartment in the presence of CMV infection. Speciﬁc studies ad-
dressed numerical and functional changes, gene expression proﬁles,
homing characteristics and maintenance mechanisms of the total
CD8+ T cells and, in particular, of the CMV-speciﬁc CD8+ T cells. The
effect of HCMV infection on CD8+T cells polyfunctionality (CD107a ex-
pression, IFN-γ or TNF-α production), has been explored in HCMV-
seropositive and seronegative young and in HCMV-seropositive
middle-aged healthy donors in response to SEB (R. Solana, Cordoba,
Spain). The results showed that the percentage of SEB-responsive
CD8+ T cells increases with both age and HCMV infection. Of interest,
young and middle-aged CMV-seropositive subjects possessed more
CD8+ polyfunctional cells than their CMV-seronegative counterparts;
this was associated with the expansion of polyfunctional CD8+
CD57+ T cells. These results suggest that being infected with HCMV
may improve the polyfunctionality and consequently the quality of
CD8+ T cells at least in young individuals. It appeared that this im-
provement was not affected by advancing age (no difference between
young and middle aged subjects), although bona ﬁde old individuals
were not studied by group. Similar studies were reported by Y.L. Chiu
(Baltimore, USA) who examined polyfunctionality (CD107a expression
IL-2, IFN-γ, TNF-α production) of the distinct CD8+ T cell subsets
(identiﬁed by staining with CD45RA andCCR7) in response to 4h PMA/
ionomycin stimulation in a group of young and elderly donors. These in-
vestigators described a general functional impairment driven by the
lack of IL-2 in the CD8+ CCR7-CD45RA+ subset (TEMRA), that expands
signiﬁcantly in the elderly. Interestingly, upon stimulation, these cells
exhibit impairment in the upregulation of pERK (phosphorylated Extra-
cellular Signal-Regulated Kinase), belonging to a key mitogenic signal
transduction pathway. Currently, potential genes involved in the
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tigation bymicroarray analysis. Although it is very likely that a substan-
tial proportion of the late-stage differentiated memory CD8+ T cells
considered in this study is HCMV-speciﬁc, the use of a nonspeciﬁc stim-
ulus limits the ability to extrapolate these results to CMV-speciﬁc CD8+
T cells.
Factors involved in the regulation of the CD8+ effector T cell func-
tion were also studied by gene expression analysis. A transcription fac-
tor speciﬁcally expressed in human cytolytic CD8+ T cells, which
accumulate signiﬁcantly in HCMV-infected people, was identiﬁed by
R. van Lier et al. (Amsterdam, The Netherlands) (Hertoghs et al.,
2010). This factor, termed HOBIT, is highly related to BLIMP-1, a tran-
scriptional repressor that regulates terminal differentiation of B and T
lymphocytes. An antibody raised against the unique N-Terminal part
of HOBIT speciﬁcally stained cytolytic subsets of human lymphocytes,
like effector-type CD8+ T-cells, but also CD28− CD4+ T cells and NK
cells. Knockdown of HOBIT in NK cell lines via siRNA reduced IFNγ pro-
duction and increased cell survival. HOBIT may be essential for control-
ling formation, maintenance and function of resting cells with
immediate effector function. Its exact contribution to the generation,
maintenance and function of resting effector-type CD8+ T cells
in vivo remains to be established.
N. Riddel, A. Akbar et al. (London, UK) investigated accumulation of
low avidity CD45RA+ HCMV-speciﬁc CD8+ T cells observed in elderly
people (Grifﬁths et al., 2013). These investigators used wild-type pMHC
tetramers and also mutated pMHC tetramers that do not bind CD8 to
identify low-afﬁnity (CD8-dependent) and high-afﬁnity (CD8-indepen-
dent) TEMRA cells. In addition to reduced TCR:MHC avidity, these cells
exhibited relatively long telomeres, suggesting that they are not in-
duced by repeated antigen-driven proliferation. Instead, IL-15 incuba-
tion was sufﬁcient to induce CD45RA re-expression in CD45RA- HLA-
A2/NLV-CMV-speciﬁc CD8+ T cells. Furthermore, HCMV stimulation
induced IL-15 production by monocytes secondary to invoking IFN-α
release by dendritic cells. These data suggest that HCMV can induce dif-
ferentiation of EMT cells that readily enter cytokine-driven homeostatic
proliferation, which may provide a mechanism by which cells with low
TCR:MHC avidity can accumulate in-vivo.
A large gap in our knowledge of HCMV-speciﬁc T cells is related to
the fact the majority of published studies have examined responses in
peripheral blood (PB) and very little is known about responses localized
to other anatomical sites. It has been shown that lymphnodes (LN) con-
tain HCMV-speciﬁc CD8+ T cells that resemble (central) memory cells,
a phenotype that is infrequent in peripheral blood (E. Remmerswaal,
Amsterdam, The Netherlands) (Remmerswaal et al., 2012). When
analysing the TCR-Vβ repertoire by high throughput sequencing it
was found that the LN HCMV-speciﬁc CD8+ T cell pool often contained
clones not found in PB. Since it is not known if human LNHCMV-speciﬁc
CD8+T cells contribute to the PB pool upon viral recall, the possible ap-
pearance of these clones in the circulating pool during CMV reactivation
was studied. In one of the four patients studied, unique LN clones were
recruited to the PB upon antigenic recall. Therefore it was postulated
that LN can contain a unique pool of “true” memory HCMV-speciﬁc
CD8+ T cells that may contribute to the PB population upon antigenic
recall. Although it is essential to look at HCMV-speciﬁc T cell responses
in compartments distinct from blood (lymphnodes, bonemarrow, lym-
phocytic inﬁltrate and also gut- and other mucosa-associated lymphoid
tissue), it is logistically and sometimes ethically very difﬁcult to carry
out these studies in sufﬁcient numbers of elderly donors. For this reason,
the standard source for studying the impact of HCMV infection on the
homeostasis of the naïve and antigen-experienced CD8+T cells will re-
main peripheral blood.
With regard to the remodeling of the memory compartment, one of
the open questions is whether the phenomenon of T cell memory inﬂa-
tion, well-described in the mouse model, also takes place in humans. In
fact, MCMV-induced T cell memory-inﬂation in inbred mouse-strains
polarizes the T cell response into usually isolated large (inﬂated) andmuch smaller (contracted) responses. While large expansions of
HCMV-speciﬁc T cells have been observed, particularly in older age, it
has remained unclear whether these occur in isolation or possibly as
part of several large responses in the same individuals with a generally
raised response level. In a recent study, F.Kern (Brighton, UK), reported
on a large T cell response dataset from short-term ex-vivo HCMV anti-
gen stimulation (measured by IFN-γ secretion) (Sylwester et al.,
2005). The dataset was re-analyzed to establish the presence of normal
CD4+ or CD8+ response ranges, response distribution across proteins
(using N200 HCMV peptide pools representing all expressed HCMV-
proteins N30 amino acids in length) and outliers in 33 healthy individ-
uals aged 19–53 years. An additional 47 old HCMV-infected participants
were tested with respect to 19 selected HCMV peptide-pools. The au-
thors concluded that the deﬁnition of outliers was complicated, because
i) individual CD4+ or CD8+ response levels varied hugely and ii) a
“protein target factor” affected response size. Interestingly, individuals
with a greater number of different responses exhibited largermaximum
responses and greater numbers of outliers. However, response domi-
nance hierarchies were regular and relatively uniform across the
donor population and marked polarization of response size as reported
in mouse models (inﬂated versus contracted) was not observed. The
study suggests that is not possible to deﬁne clinically useful normal
ranges for HCMV-speciﬁc T cell responses applicable to cross-sectional
data, as response sizes vary hugely depending on both protein target
and individual. Moreover, the occurrence of T cell memory-inﬂation
similar to the mouse model in HCMV infection is not supported by
this analysis (manuscript submitted).
The methodological approach of the previous study tried to bypass
the limits of currently and commonly used tests for the evaluation of
HCMV-speciﬁc T cell responses, an extremely demanding task because
of the breadth of such responses. In fact, functional assayswith intracel-
lular cytokine staining in cells activated with one or two
immunodominant proteins (generally, pp65 and/or IE-1 proteins), and
ﬂow cytometry staining with peptide-MHC multimers, both provide
only a partial insight into the HCMV-speciﬁc T cell responses. In line
with this critical issue, a different method for the determination and
quantiﬁcation of HCMV-speciﬁc T cells has been developed by D.
Lilleri's group (Pavia, Italy) following stimulation with HCMV-infected
autologous dendritic cells (Lozza et al., 2005) using intracellular detec-
tion of IFN-γ production. In a group of 31 healthy adult controls, the T
cell response evoked by the infected dendritic cell stimulationwas com-
pared with the response against an HCMV-infected cell lysate and the
response against a peptide pool including 34 peptides relevant to mul-
tiple HCMV proteins shown to carry epitopes recognized by MHC class
I-restricted CD8+ T-cells. The DC assay appeared to be the test of choice
both in terms of quantitative and qualitative characterization
(polyfunctional proﬁle for IFN-γ, TNF-α and IL-2 production and
CD40L upregulation) and this DC assay may be suitable for testing
HCMV-speciﬁc responses also in the elderly.
The naive T cell compartment is known to decline in aging, but one
basic question concerns the distinction between the relative effects of
anti-CMV T cell responses and aging itself. To distinguish which of the
manifestations of T cell aging occur in its absence (T cell aging per se)
and which only and solely in the presence of HCMV, (HCMV-associated
T cell aging) a cross-sectional study using large cohorts of HCMV-
seropositive (HCMV+) and CMV-seronegative (HCMV−) individuals
across different age groups was performed (J.Nikolich-Zugich, Tucson,
USA). The results of this study, extended since last year's report, showed
that while percentages of naïve CD8 T cells declined and those of mem-
ory T cells increased with aging, in HCMV− individuals this was solely
due an absolute numerical loss of naïve T cells (deﬁned using up to 5 dif-
ferent markers). Consequently, HCMV− individuals exhibited ﬂat or
declining absolute numbers of memory T cells. Only in the presence of
HCMV was there an absolute increase of memory cells, which was di-
rectly linked to the inﬂation of the effector memory CD8+ (and much
less CD4+) cell pool. Moreover, memory inﬂation with age increased
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those whose anti-HCMV titers remained in the lower half. If indeed
higher Ab titers can be taken as a reliable correlate of virus reactivation
and of poor virus control, then these results raise the possibility that ef-
ﬁcacious HCMV control may circumvent drastic changes in the periph-
eral T cell subset balance previously associated with this virus. These
results, however, will have to be conﬁrmed in longitudinal studies.
Nonetheless, the fact that naïve T cells disappeared from HCMV+ indi-
viduals relative to age in the essentially the samemanner as in HCMV−
subjects suggests that HCMV may have very little to do with the main-
tenance of naïve CD8+ T cell numbers.
In a different study using a mouse model, the impact of deliberate
early-life MCMV infection upon the maintenance of the naïve CD8 T
cell repertoire was addressed (M. Smithey, Tucson, USA). While the re-
sults of this study agreed with prior studies (Cicin-Sain et al., 2012)
(Mekker et al., 2012) that naïve T cell numbers did not decline any faster
during life-long MCMV infection, evidence that there is a decline in
functional immunity (polyfunctionality, responding cell numbers),
and, more importantly, in the numbers of naïve precursors speciﬁc for
the B8R and OVA epitopes was found (Smithey et al., 2012). Further,
in response to infectious challenge, therewas a complete lack of overlap
in clonal TCRβ utilization by single-cell PCR between the mice aged in
the presence or absence of life-long MCMV infection.
In the past years, in an attempt to elucidate the impact of persistent
HCMV infection on immune status, studies in selected elderly popula-
tions have been intensiﬁed. However, when studies include people
who have reached an age greater than the average life expectancy, it
must be considered that a “survivor bias” can skew the population. In
fact, the results obtained in such a selected populations may not be
easily generalized to a normal aging but rather linked to longevity.
In order to clarify to what degree alterations at the T cell level are
associated with the proﬁle and function of humoral immune responses
to HCMV, and to explore the biological relevance of IgG titers,
E. Derhovanessian, G. Pawelec and collaborators (Tübingen, Germany)
studied neutralizing Ab activity of sera in 79 elderly individuals over
the age of 83 participating in the BELFRAIL study (Vaes et al., 2010).
The assay (performed by K. Schweinzer & K. Hamprecht, Dept. Virology,
Tübingen) determined the ability of the subject´s serum to prevent the
in vitro infection of a susceptible epithelial cell line by a clinical isolate
of CMV. In this group of subjects a higher neutralizing antibody capacity
in serum was associated with a lower CD4/CD8 ratio and a more late-
differentiated CD8 compartment (lower frequency of naive and higher
frequency of late-differentiated effector phenotypes and higher frequen-
cy of CD57+ cells). The neutralizing activity of the serum was remark-
ably strong, even more so than control sera from young women. This
emphasizes the high-level commitment of immune resources to CMV-
immunosurveillance not only in terms of cellular responses, but also hu-
moral responses. Another study in the same cohort (C.Mathei, Leuven,
Belgium) analyzed T cell subsets of 235 community-dwelling persons
aged 81.5 years or older (73.6% HCMV+) and 25 younger persons
with an average age of 28.5 yr (12% HCMV+). In the elderly, a total of
7.2% had an inverted CD4/CD8 ratio, which was signiﬁcantly associated
with HCMV infection (88% HCMV+), less naïve and more late-
differentiated CD4 and CD8 T-cells. 32.8% of the elderly (62.3%
HCMV+) had a CD4/CD8 ratio N5, compared to none in the young indi-
viduals. Those with ratios N5 hadmore naïve and less late-differentiated
CD4 and CD8 T-cells, compared to thosewith a ratio b1, ratios between 1
and 5 or the younger individuals. Furthermore, a CD4/CD8 ratio N5 was
signiﬁcantly associated with a lower physical and global performance.
Thus, this study identiﬁed a previously unrecognized subgroup in the
very elderly with an exceptionally high CD4/CD8 ratio showing a lower
functional performance and a dominant naïve T-cell phenotype. These
ﬁndings, together with those from the Leiden 85-Plus study, showing a
better 8-year survival for very elderly individuals with a lower frequency
of naïve CD8 T-cells, suggest that, under certain circumstances, the
HCMV-associated changes in blood T cell subsets might not be asdetrimental aswidely believed but rather could represent an adaptation-
al remodelling of the immune system at very old age to deal with the
burden of the virus by maintaining essential immunosurveillance
(Derhovanessian et al., 2013).
Using a transcriptomic analysis approach, M. Hurme (Tampere,
Finland) explored themechanisms involved in the association between
high levels of anti-HCMVantibodies in elderly individuals andpatholog-
ical sequelae (Kuparinen et al., 2013). The correlation between the anti-
HCMV IgG titre and global gene expression proﬁle was determined in
HCMV-seropositive nonagenarians and in young controls. In controls,
the correlating genes belonged to pathways known to regulate normal
cellular immunity, but in contrast to this, in nonagenarians several path-
ways involved in apoptosis and cellular damage were activated. Thus, it
seems that HCMV-associated pathological effects are more prominent
in elderly individuals.
In another study C. Franceschi and collaborators (Bologna, Italy)
determined HCMV prevalence in 132 centenarians, 245 centenarian
offspring and 101 offspring of non long-lived parents. The prevalence
of HCMV positivity was high, ranging from 91.0 to 94.1% in centenarian
offspring and offspring of non long-lived parents, respectively, and
reaching 94.7% in centenarians. After stratiﬁcation for the levels of
HCMV-IgG antibodies, centenarians in the highest antibody group
showed signiﬁcantly higher levels of creatinine, higher absolute num-
bers of lymphocytes, neutrophils and platelets and lower levels of
HDL-cholesterol, compared to those low-positive or negative for
HCMV-IgG. In addition, high-positive HCMV-IgG centenarians showed
higher numbers of differentiated helper and cytotoxic T lymphocytes
and a lower CD4/CD8 ratio. Centenarians and their offspring
(n = 104) were predominantly HCMV-positive, while offspring of
HCMV-negative centenarians were either positive or negative, suggest-
ing a possible familial component inﬂuencing susceptibility to HCMV
infection. Overall, these data may indicate that HCMV positivity does
not inﬂuence the chance of reaching extreme longevity, although
survivor selection needs to be studied further.
4. HCMV infection: good or bad player in immunosenescence and in
human diseases?
One dominant remaining question, which keeps stimulating intense
research efforts, is whether HCMV infection has only negative or at least
some beneﬁcial effects on the immune status and overall health.
Using a systems immunology approach, D. Furman,M.M. Davis and
collaborators (Palo Alto, USA) obtained provocative data showing very
different immunological and gene expression proﬁles in HCMV infec-
tion and aging. They studied longitudinally a cohort of 89 subjects of dif-
ferent age groups that were genotyped for immune-related SNPs and
assayed for baseline levels of a variety of blood measures including
serum cytokines and chemokines, whole-genome gene expression and
cell subset frequencies. They also studied the functional activity of
some of these subsets by in vitro stimulation of cells with cytokines,
and in vivo humoral responses to seasonal inﬂuenza vaccination. Robust
immune responses were observed in HCMV-seropositive vs seronega-
tive young but not older individuals, as seen by the increased pSTAT re-
sponses and higher antibody response to the inﬂuenza vaccine. The
authors also showed that the variation in CD4+ CD28− cell counts
due to HCMV can be genetically explained by a set of SNPs on the HLA
locus. The conclusion of this study is that HCMV and aging have sig-
niﬁcantly different inﬂuences on the immune system and that HCMV
might have a beneﬁcial effect in young individuals, reminiscent of the
conclusions reached by Solana and coworkers above (see the beginning
of section B).
The impact of the CMV infection on immune ﬁtness was also
explored by testing the efﬁcacy of the adaptive immune system of
mice latently infected with MCMV by challenging them with vesicular
stomatitis virus (VSV). The results of this study (L. Cicin-Sain, T.
Marandu, Braunschweig, Germany) indicated that latent MCMV
59P. Sansoni et al. / Experimental Gerontology 55 (2014) 54–62infection reduces the relative, but not the absolute, count of CD8 cells
responding to a challenge with an unrelated virus. The reason for this
discrepancy was identiﬁed in the large increase of the effector-
memory (EM) subset of CD8 T cells, which doubled the size of the
CD8 compartment in MCMV-infected mice. Consequently, due to the
increased size of the CD8 pool, the fraction of the antigen-speciﬁc
response to the challenge virus relative to the CD8 compartment
diminished, while the size of the response in absolute terms remained
the same.
P. Thomas (Memphis, USA) also used a mouse model of CMV infec-
tion, examining its impact on inﬂuenza virus co-infection. Acute and
early latent MCMV infection resulted in improved control of inﬂuenza
virus infection as measured by reduced weight loss and increased viral
clearance. MCMV-speciﬁc CD8+ T cells were found to inﬁltrate the
lungs of inﬂuenza-infected animals several days prior to the emergence
of an inﬂuenza-speciﬁc CD8+T cell response. These cells did not appear
to cross-react with inﬂuenza epitopes, but were capable of producing
signiﬁcant amounts of the cytokines IFN-γ and TNF-α. Using IFN-γ
knockout mice, it was shown that the protective effects of prior
MCMV infection were entirely dependent on IFN-γ, likely produced by
these MCMV-speciﬁc CD8+ T cells in a bystander manner. This, as
well as some other studies above, was consistent with the ﬁndings
from the Virgin laboratory (Barton et al., 2007) that persistent viruses
can protect against heterologous infections, at least in youth. It would
be of interest to examine whether inﬂuenza virus-induced cytokines
played a role in stimulating CMV-speciﬁc effectormemory T cells to pro-
duce IFN-γ.Conversely, another study documented negative effects of
HCMV seropositivity on the in vivo and in vitro B cell responses to the
seasonal inﬂuenza vaccine (D. Frasca, Miami, USA). The in vivo re-
sponse was evaluated by hemagglutination inhibition assay to measure
antibody titers and by ﬂow cytometry to measure the percentage of
switchedmemory B cells. The switchedmemory B cells can be detected
in blood before vaccination and their levels predict the robustness of the
in vivo response. The in vitro response was measured by AID (activa-
tion-induced cytidine deaminase), the enzyme of immunoglobulin
class switch recombination that generates protective antibodies. AID is
another B cell biomarker predictive of optimal in vivo responses. Results
presented indicate that HCMV seropositivity signiﬁcantly decreases
both in vivo and in vitro B cell responses to the vaccine in both young
and elderly individuals, possibly through an increase in intracellular
levels of B cell-derived TNF-α, which has previously been shown to be
predictive of poor B cell function.
Altogether, the above studies underlined that changes in immune
system homeostasis of CMV infected hosts do not result in a general
functional impairment and that, in speciﬁc contexts, particularly in
younger individuals, CMV infection could even improve some immune
responses.
5. CMV and pathologies of aging
However, despite these intriguing new observations, persistent
HCMV infection has been associated with a range of clinical complica-
tions and the signiﬁcance of these associations is now under investiga-
tion in a number of laboratories. In fact, the causal relationship
between HCMV infection and health status in the elderly remains am-
biguous and poorly addressed from a prognostic and therapeutic point
of view. One important point to be clariﬁed is whether there are deﬁned
clinical situations in which either a dysregulated anti-HCMV immune
response or viral reactivation may pose an increased clinical risk for el-
derly patients. Results from studies carried out in several pathological
conditions were presented and discussed.
5.1. Immunosuppression and CMV
B. Grubeck-Loebenstein (Innsbruck, Austria) presented an analysis
of T cell function and the composition of the T cell repertoire in kidneytransplanted immunosuppressed patients of different ages, compared
with age-matched controls. HCMV-seropositive and -seronegative pa-
tients and control groups were also compared. Independent of age and
HCMV status, the production of IL-2 and IFN-γ by T cells was decreased
in the immunosuppressed patient groups. CXCR5 expression on T cells,
which negatively correlates to endogenous IL-2 signaling, was increased
in patients compared to controls but this parameter did not differ
among patients of different age and HCMV status. In HCMV-
seronegative patients, kidney transplantation and immunosuppressive
therapy did not induce changes in the CD8+ T cell pool, but there was
a moderate increase in CD4+ CD28− effector T cells when compared
to age-matched controls. In contrast, HCMV infection triggered a shift
from early to late differentiated CD4+ and CD8+ T cells in both immu-
nosuppressed patients and controls. This shift was most pronounced in
elderly transplant patients under immunosuppressive therapy. The
results demonstrated that immunosuppressive therapy following
kidney transplantation was effective in patients older than 60 years of
age. Persistent HCMV infection did, however, accelerate age-related
changes in the T cell compartment in elderly persons under immuno-
suppressive therapy (Welzl et al., 2014).
5.2. CMV, survival and cardiovascular disease
Although some studies have linked high HCMV antibody titres with
mortality in elderly cohorts (Strandberg et al., 2009) (Wang et al.,
2010), the relationship between HCMV infection and mortality among
immunocompetent individuals still remains to be conﬁrmed.Moreover,
the mechanisms underlying this relationship are not known, even as
accumulating evidence links HCMV infection to an increased incidence
of cardiovascular disease.
In a cohort of 67 healthy elderly an aberrant HCMV-speciﬁc (pp65) T
cell response, without chemokine or cytokine co-expression (CD107a+
PRF1+ but IFNγ-TNFα-IL2-MIP1α-) was found to be increased in indi-
vidualswith lower survival rates andwas found to be independently as-
sociated with time to all-cause death (S. Ferrando-Martinez, Seville,
Spain). This result suggests that accumulation of CD107a+ PRF1+
(IFNγ-TNFα-IL2-MIP1α-) CD8+ HCMV-speciﬁc T cell responses could
be a useful tool to identify individuals with age-related immune dereg-
ulation and a higher risk of death, providing a new surrogate marker of
immune system deregulation in late stages of life. In another study
(P.Moss, Birmingham, UK), an 18 year follow-up of 511 elderly donors
aged over 65 years at entry showed that those who were HCMV-
seropositive at study entry had a near 4 year reduction in lifespan com-
pared to those who were uninfected (Savva et al., 2013). Interestingly,
this was entirely due to a two-fold increase in mortality from vascular
disease. Also, another recent study (Wall et al., 2013) investigated the
relationship between HCMV seropositivity within patients with chronic
kidney disease and carotid-femoral pulsewave velocity (PWV), the cur-
rent gold-standard measure of arterial stiffness. It was shown that
HCMV infection is associated with an increased arterial stiffness, per-
haps partly explaining the vascular complications seen in these patients.
E. Shin (Daejeon, Republic of Korea) employed a similarmethodological
approach in a cohort of subjects with normal renal function. Arterial
stiffness was evaluated by heart-femoral pulse wave velocity (PWV)
in a cohort of 423 Koreans, and PWV-associated immune parameters
were analyzed. The frequency of CD57+ cells in the CD8+ T cell popu-
lation signiﬁcantly correlated with PWV in multivariate analysis. A sub-
group of 123 subjects was further analyzed for HCMV-speciﬁc immune
responses. All the subjects (aged ≥50 years) were seropositive for
HCMV IgG. Moreover, HCMV pp65-speciﬁc IFN-γ or TNF-α secretion
by CD8+ T cells signiﬁcantly correlatedwith PWV in multivariate anal-
ysis. These ﬁndings suggest that CD57+ CD8+ T cells and secretion of
IFN-γ and TNF-α byHCMVpp65-speciﬁc CD8+T cellsmight contribute
to increased arterial stiffness, a predictor of cardiovascular mortality.
Finally, a recent paper by Terrazzini et al. has conﬁrmed that resting
blood pressure is linked to the size HCMV-speciﬁc CD8+ T cell
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ing CD25, CD39 and CD134 upon activation with CMV-Antigen
(Terrazzini et al., 2013).
5.3. CMV and diabetes
HCMV infection aswell as its reactivationwere reported to be strong
predictors of diabetes mellitus onset when the host immune response
to infection is diminished, for instance after kidney, heart and lung
transplantation. Even asymptomatic HCMV infections within the con-
text of transplantation have been shown to impair insulin release.
Beta-cells are themselves susceptible to infection by HCMV, which
could potently activate a beta-cell toxic immune response. This provid-
ed the rationale to assess the relationship between HCMV seropositivity
and HCMV-IgG antibody levels and new onset of type 2 diabetes
(incident T2D) (E. Gkrania-Klotsas, Cambridge, UK). Data from 12,260
participants of the EPIC (European Prospective Investigation of
Cancer)–Norfolk prospective cohort were analyzed, with full covariate
information, including 532 ascertained incident 2TD cases. After adjust-
ment for age, sex, body-mass index, physical activity, family history of di-
abetesmellitus, smoking and socioeconomic status, the presence or level
of IgG against HCMV were found not to be associated with the risk of
incident T2Dover an average follow-up of 10.2 years. Thus, in this cohort
of immunocompetent people, prior infectionwithHCMV and the level of
HCMV-IgG were not associated with the risk of incident T2D.
5.4. CMV, cognitive impairment and depression
Three different studies in the Workshop reported on the controver-
sial issue of HCMV infection and mental health. A study of 1061 partic-
ipants of the Lothian Birth Cohort found a small but signiﬁcant decrease
in cognitive function in HCMV-seropositive donors (P.Moss, Birming-
ham, UK) (Gow et al., 2013). Interestingly the largest effect was seen
in people with the highest HCMV-speciﬁc antibody levels. Within the
group with the highest quartile of antibody titer, the general cognitive
ability was reduced by nearly 1%. The magnitude of this reduction is
similar to the effect of the strongest genetic determinants of cognitive
decline determined so far in this cohort.
Two longitudinal studies, examining the association between persis-
tent pathogens including HCMV, inﬂammatorymarkers and depression
using data from theDetroit NeighborhoodHealth Study (DNHS) and the
Sacramento Area Longitudinal Study of Aging (SALSA), were presented
(A.M. Simanek, Milwaukee, USA). Among 209 DNHS participants, free
of depression and seropositive for HCMVat baseline, the odds (95% con-
ﬁdence interval) for onset of depression in the ﬁrst year of the study
were 2.89 (1.13, 7.42) for those with HCMV IgG antibody titers in the
highest quartile compared to those in the lowest three quartiles, con-
trolling for age, gender, race/ethnicity, income level, number of stressful
life events and medications. Among 428 SALSA participants, HCMV se-
ropositivity but not IgG antibody titer was associated with a 1.65-fold
greater incidence rate of reporting elevated depressive symptoms over
nine years of follow-up, adjusting for age, gender, education level,
acculturation level (i.e. Mexican vs. Anglo cultural orientation), nativity
status and medication use. These associations were not mediated by
inﬂammatory factors according to markers including interleukin-6 or
C-reactive protein.
Future research should help elucidate the biologic mechanisms by
which HCMV infection and immune responses against HCMV may in-
crease risk of onset of adversemental health outcomes such as cognitive
impairment and depression.
5.5. CMV and cancer
Available evidence demonstrates that HCMV is present in several
solid tumors with a high prevalence, approaching 100% in malignant
glioblastoma (Rahbar et al., 2013). The virus may mediate bothoncomodulatory and oncogenic effects. It has been demonstrated
that anti-viral treatment with valganciclovir against HCMV-positive me-
dulloblastoma and neuroblastoma tumors in animal xenograft models
prevents tumor growth (Wolmer-Solberg et al., 2013), and that
valgancilovir treatment in glioblastoma patients shows promise in in-
creasing patient survival rate (Stragliotto et al., 2013). In this Workshop,
C. Söderberg-Nauclér (Stockholm, Sweden) presented new data on this
topic. This group analyzed serum and blood samples of glioblastoma pa-
tients and found a high proportion of patients free of detectable HCMV-
speciﬁc IgG antibodies in serum, who were nonetheless HCMV-positive
in the tumor. Moreover, compared to control subjects, glioblastoma pa-
tients had an altered T cell response against HCMV, suggestive of chronic
HCMV reactivation and possibly exhaustion of the immune response.
Thus, immunological disturbances in glioblastoma patients have been
conﬁrmed and these alterations need to be investigated further in order
to design an optimal therapeutic strategy targeting HCMV.
5.6. CMV and rheumatoid arthritis
It has already been described that late-differentiated T cells in pa-
tients with rheumatoid arthritis (RA) are characterized by the loss of
the costimulatorymolecule CD28 and increased expression of inhibitory
NK cell receptors like LIR-1. Because chronic infection with HCMV con-
tributes to an expansion of these cells, K. Rothe (Leipzig, Germany)
studied the inﬂuence of HCMV seropositivity on LIR-1 expression in
CD8+ T cells of RA patients. Patients had increased frequencies of
LIR-1+ CD8+ T cells compared to healthy individuals. In RA patients
as well as in the healthy controls, there were higher frequencies of
LIR-1+ CD8+ T cells in CMV-seropositive compared to seronegative
individuals. In addition, RA patients with strong LIR-1 expression
had higher disease activity scores. Importantly, HCMV− LIR-1+
HLA*A0201 -tetramer+ CD8+ T cells were more frequent in RA pa-
tients as compared to HCMV+ healthy controls. Furthermore, analysis
of the cytolytic potential after HCMV restimulation revealed higher
percentages of CD107a+ CD8+ T cells in RA patients than in healthy
donors. One interpretation of these results is that HCMV-speciﬁc T
cells, involved in containing latent HCMV infection, might potentially
also contribute to disease severity in RA patients. Alternatively,
RA-associated inﬂammatory process and immunopathology could be
inducing CMV reactivation at a higher rate in RA subjects.
5.7. CMV and acute and chronic inﬂammatory diseases
T. Fulop et al. (Sherbrooke, Canada) evaluated the impact of HCMV
serostatus on biological and immune parameters of elderly subjects suf-
fering from acute inﬂammation (hip fracture, n = 23) in comparison
with chronic inﬂammatory diseases such as Diabetes Mellitus type 2
(T2DM, n=50). In an acute stress situation, such as recent hip fracture,
HCMV seropositivity had no effect on blood parameters. T cell prolifer-
ation induced by speciﬁc TCR stimulation with antiCD3/antiCD28
mAbswas notmodulated either. However, innate immune cell function,
including phagocytosis and phagoburst, were depressed for a long peri-
od of time, extending at least 6 months, only in HCMV-seropositive
patients, while seronegative patients returned to baseline after
6 weeks. In a chronic stress situation (T2DM), HCMV inﬂuenced the
CD8+ subpopulations, so that the percentages of CD8+ naive cells
were decreased and the percentages of CD8+ TEMRA cells were
increased independently of T2DM. T2DMandHCMV-seropositivity con-
comitantly increased CD57 expression on the CD8+ subpopulation.
Dissecting the respective effects on immune alterations in elderly
individuals of diseases and CMV infection remains a challenge.
5.8. CMV and acute illnesses
The great majority of presented studies explored the impact of
HCMV infection in chronic disease, not acute illnesses, thus avoiding
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ious reports have shown that HCMVmay reactivate surprisingly often in
critically ill immunocompetent adult patients. Some of these reports
have also suggested that systemic viral reactivation may prolong hospi-
tal stay andmortality. Nevertheless, it is currently unknownwhether el-
derly patients in critical care settings may have an increased risk of viral
reactivation. To that effect, F. Fagnoni (Parma, Italy) presented the de-
sign of a prospective observational trial to examine the potential clinical
risk linked to HCMV-speciﬁc immune responses and possible viral reac-
tivation in elderly patients suffering from acute stroke.
An increasing amount of data is accumulating about the interactions
among CMV infection, immunosenescence and age-related diseases.
Thus, at the end of the Workshop, a general consensus was expressed
for the proposal (A. Maier, Amsterdam, The Netherlands) to include
meta-analyses, based on HCMV serostatus and HCMV-speciﬁc IgG
titer, in design of current studies. All the researchers involved in this
topic should move toward genetic, clinical phenotype or mortality
studies, possibly using the same adjustment models.
6. Conclusions
A number of longstanding questions related to CMV's role as a “driv-
er” or “passenger” in the aging of the immune system, in age-related
diseases and in complex comorbidities remain incompletely resolved
and rather recalcitrant to being rapidly and conclusively resolved. Part
of the obstacle lies in the complexities of longitudinal human studies,
with pronounced ethical barriers and genetic and epigenetic variabil-
ities on the one hand, and the imperfect concordance between human
infection andmore tractable animalmodels of CMV infection in a specif-
ic pathogen-free and genetically homogenized settings, on the other.
Nonetheless, this Workshop brought about important new ﬁndings
that expand our knowledge and challenge it with new and stimulating
questions. Amongst those, we believe that four are particularly worth
highlighting:
• HCMV infection and aging seem to ‘operate’ over different, at best only
partially overlapping, immune traits
• Susceptibility to immune alterations in HCMV-seropositive subjects is
not only highly variable, but could be genetically determined
• HCMV infection might boost immunity in young individuals and in
particular contexts, as in very old people, could have beneﬁcial effects
• Presented data suggest that the interplay between the efﬁcacy of viral
control, extent and frequency of viral reactivation and the
superimposed comorbidities need to be studiedwith utmost urgency.
Validating the above observations and attacking the main
longstanding questions related to the positive or deleterious effects of
CMV remains an important task confronting researchers in the ﬁeld in
the future.
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